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Endocrine sequelae after treatment
for childhood medulloblastoma
Powikłania endokrynologiczne po zakończeniu leczenia medulloblastoma u dzieci
A B S T R A C T
INTRODUCTION. Endocrine abnormalities in children after treat-
ment for medulloblastoma (PNET, primitive neuroectodermal tu-
mour) may concern one or more hormones and may appear at
different periods of time following therapy.
MATERIAL AND METHODS. The examination was performed on
a group of 23 children (age 1–18 years) treated for medulloblasto-
ma/PNET by neurosurgery, radio-, and chemotherapy (22 children),
or neurosurgery with chemotherapy (1 child). Before the initiation
of the therapy, auxological measurements and hormonal investi-
gations were performed. Three children died during the therapeu-
tic process. For the rest, the examinations were repeated every
3–6 months for the 3 years after completion of the treatment.
RESULTS. No pre-therapy abnormalities were noted in the ana-
lyzed group. In the first 3 years after medulloblastoma treatment
endocrinology disorders were found in 8 patients. Five patients
presented with a single disorder, 2 patients had 2 abnormalities,
and 1 patient manifested 3 disorders. Decreases in growth veloci-
ty (in 7), including growth hormone deficiency in (4) primary hy-
pothyroidism (in 3), hypogonadotropic hypogonadism (in 1), and
osteoporosis (in 1), were found. Decreases in height velocity ap-
peared 4–24 months after the treatment, and hypothyroidism after
7–34 months. Hypogonadism was the first complication, observed
3 months after treatment, and osteoporosis was noted 19–
–24 months after medulloblastoma treatment.
CONCLUSIONS. Children, after radio- and chemotherapy for
medulloblastoma/PNET, are a group at risk of developing late en-
docrine complications. We suggest the protocol of long-term fol-
low-up medulloblastoma survivors, based on clinical symptoms
and hormonal and radiological examinations.
Key words: medulloblastoma/PNET, children, endocrine sequelae
Endocrionology, Obesity and Metabolic Disorders 2009, vol. 5, No 1, 1–6
S T R E S Z C Z E N I E
WSTĘP. Zaburzenia endokrynologiczne po leczeniu medullobla-
stoma/PNET (primitive neuroectodermal tumours) u dzieci mogą
dotyczyć wydzielania jednego lub kilku hormonów i występować
w różnym okresie od zakończenia terapii.
MATERIAŁ I METODY. Badaniu poddano grupę 23 dzieci w wieku
1–18 lat leczonych z powodu medulloblastoma/PNET z zastoso-
waniem operacji neurochirurgicznej, a następnie radio- i chemio-
terapii (22 dzieci) oraz operacji neurochirurgicznej z następową
chemioterapią (1dziecko). Przed rozpoczęciem leczenia u wszyst-
kich dzieci przeprowadzono pomiary auksologiczne oraz badania
hormonalne. Troje dzieci zmarło w trakcie leczenia. U pozostałych
badania powtarzano co 3–6 miesięcy przez 3 lata od zakończenia
leczenia.
WYNIKI. W grupie 23 dzieci przed rozpoczęciem leczenia nie ob-
serwowano żadnych zaburzeń. W pierwszych trzech latach od
zakończenia leczenia z powodu medulloblastoma/PNET zaburze-
nia wystąpiły u 8 pacjentów. U 5 były to pojedyncze zaburzenia,
u 2 wystąpiły dwa zaburzenia, a u 1 pacjenta trzy zaburzenia. Ob-
serwowano: zwolnienie szybkości wzrastania (u 7) z niedoborem
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hormonu wzrostu (u 4), pierwotną niedoczynność tarczycy (u 3),
hipogonadyzm hipogonadotropowy (u 1) oraz osteoporozę (u 1).
Zwolnienie szybkości wzrastania wystąpiło w okresie 4–24 miesię-
cy po zakończonym leczeniu, niedoczynność tarczycy w okresie
7–34 miesięcy, hipogonadyzm pojawił się najwcześniej, bo już po
3 miesiącach od zakończenia leczenia, a osteoporoza w okresie
19–24 miesięcy.
WNIOSKI. Dzieci poddane radio- i chemioterapii z powodu medul-
loblastoma/PNET stanowią szczególną grupę ryzyka późnych po-
wikłań endokrynologicznych. Wskazuje to na konieczność stwo-
rzenia protokołu długoterminowego monitorowania tych pacjen-
tów opartego na objawach klinicznych, badaniach hormonalnych
i radiologicznych.
Słowa kluczowe: medulloblastoma/PNET, dzieci, powikłania en-
dokrynologiczne
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Introduction
Medulloblastoma is the most frequent primary bra-
in tumour in children, accounting for as much as
10–20% of central nervous system (CNS) solid tumours,
and approximately 40% of all posterior fossa tumours
[1–3]. It may appear at any age, but ¾ of all medullo-
blastoma cases are observed in children. The highest
rate of incidence is in the age range 3–5 years. It is
more common in boys than in girls (1.5:1) [1, 5]. Me-
dulloblastoma is a poorly differentiated, highly mali-
gnant, highly invasive neuroepithelial embryonal tumo-
ur with a high propensity to disseminate in the whole
CNS [1]. Together with pineoblastoma, ependymobla-
stoma, retinoblastoma, neuroblastoma and esthesio-
neuroblastoma, medulloblastoma belongs to the gro-
up PNET (primitive neuroectodermal tumours).
Current treatment for medulloblastoma includes
surgery with the following adjuvant chemotherapy (in
children under 3 years of age), regardless of the extent
of the procedure, and adjuvant chemotherapy with cra-
niospinal radiation in children over 3 years of age [1].
There is a high risk of late consequences in patients
after medulloblastoma treatment, which is caused by
tumour treatment, as well as a risk of relapse. Mortality
rates due to medulloblastoma are 15 times higher com-
pared to the normal population. Late consequences
caused by brain irradiation may include: endocrine di-
sorders, impaired or destroyed hearing, and mental
retardation.
There is a positive correlation between the total dose
of radiation, the way of fractionation, and the dysfunc-
tion of the hypothalamo-pituitary axis [1]. For this re-
ason, there is a tendency to reduce the dose of irradia-
tion to limit its adverse effects, at the same time main-
taining treatment efficacy [1]. Another cause of late
endocrine post-therapeutic complication may also lie
in chemotherapy.
Depending on the local medical centre, there are
different protocols for monitoring potential endocrine
consequences of childhood medulloblastoma. To date,
there is no universal protocol in our country.
Objective
The objective of the current investigation was to exa-
mine the impact of the treatment for childhood medullo-
blastoma/PNET on the incidence of the late endocrine
consequences in children and adolescents following
completion of therapy, as well as an attempt at develo-
ping a protocol for detection of such complications.
Material and methods
The prospective investigation included 23 children
(9 girls, 14 boys) aged 1–18 years treated for medullo-
blastoma/PNET. Two of them died during the therapy
and another died after 3 years because of recurrent
disease. Before the initiation of the therapy, in all ca-
ses, auxological measurements (body weight, growth
velocity, nutritional status) and hormonal investigations:
ACTH, cortisol, TSH, fT4, fT3, IGF-1, LH and FSH, were
performed. All the children had undergone neurosur-
gical treatment followed by adjuvant chemotherapy and
radiotherapy (22 cases) or chemotherapy alone (one
child under 3 years of age). The chemotherapy was
performed according the SIOP protocol (before irra-
diation — vincristin, carboplatin, etoposide, endoxan;
maintenance chemotherapy — cisplatin, lomustin, vin-
cristin). Irradiation therapy was applied to the entire
central nervous system (CNS), i.e. the spinal cord and
brain, at the dose of 35 Gy, increasing to 54Gy when
irradiating the site of the removed tumour.
In all cases the auxological measurements and
hormonal investigations were repeated after comple-
tion of the treatment, 3 months after the treatment, and
every 6 months for 3 years after the treatment. Growth
hormone (GH) stimulation tests were performed in pa-
tients that presented auxological symptoms of GH de-
ficiency (a decrease of the growth velocity below
— 2SD for sex and age or below the predicted final high
— MPH - and delayed bone age over 2 years in com-
parison to the chronological age). Bone density was
measured in 2 patients with GH deficiency and in
1 patient with hypogonadotropic hypogonadism. Prima-
ry hypothyroidism was defined as decreased fT4 and
3
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fT3 levels with an elevated TSH level; secondary hypo-
thyroidism was defined as decreased fT4 and fT3 with
a low TSH level. Growth velocity deceleration was reco-
gnised when a decrease of growth rate was at least
1 SD in a 6-month observation period. GH deficiency was
diagnosed when the auxological criteria and serum GH
secretion in the standardized growth hormone stimu-
lation test was below 10 ng/ml. Any 2 of the following
3 stimulation tests were performed: clonidine test (a sin-
gle oral dose of 150 mcg/m2, blood samples were ta-
ken before and 30, 60, 90, and 120 minutes after cloni-
dine), glucagon test (a single intramuscular dose of
0.03 mg/kg body mass, not more than 1 mg, blood
samples were taken 30 minutes before injection and 0,
60, 90, 120, 150, and 180 minutes after glucagon ad-
ministration), insulin test (a single, subcutaneous dose
of 0.05–0.1 IU/kg body mass, blood samples were ta-
ken before and 30, 60, 90, and 120 minutes after insu-
lin administration). Hypogonadism was defined as
a lack of breast development after 13 years of age in girls
and lack of testes enlargement (volume < 4 ml) after
14 years of age in boys, as well as no progress to full
sexual development in 4 years from the first signs the-
reof. Hypogonadotropic hypogonadism was recogni-
zed when concentrations of sex hormones and gona-
dotropins were below normal range. Hypergonadotro-
pic hypogonadism was recognized when, in a patient
with low concentrations of sex hormones, increased
concentrations of LH and FSH were found. The hor-
mone level analysis was performed using the following
methods: TSH, fT3, fT4, LH, and FSH with the LIA me-
thod (Bayer), ACTH–IRMA, Brahms, GH–IRMA, Pola-
ton, IGF-I–IRMA, Biosearch. The reference levels for the
hormones were obtained from the Department of Bio-
chemistry in our Hospital.
Osteoporosis was diagnosed when a decrease in
bone mineral density in reference to bone age yielded
a Z-score below — 2SD in densitometry (DEXA).
Results
In the study group of 23 patients, no pre-therapy
abnormalities were noted in auxometric measurements
or hormone levels. In the first three years after medul-
loblastoma treatment, endocrine disorders were found
in 8 patients (3 boys aged 6, 13, and 17 years, and
5 girls aged 9, 9 and 8/12, 10, 11 and 14 years). Five
patients presented with single disorder, 2 with two ab-
normalities, and 1 patient manifested three disorders.
Fifteen patients showed no endocrine disorders (Fig.
1). Among the patients with 2 disorders, 1 child pre-
sented with a decrease of growth rate and primary hy-
pothyroidism, and the other with GH deficiency and
osteoporosis. The patient with 3 disorders manifested
growth retardation, primary hypothyroidism, and hy-
pogonadotropic hypogonadism (Fig. 1).
The most common abnormalities included decele-
rated growth velocity (n = 7), followed by primary hypo-
thyroidism (n = 3), hypogonadotropic hypogonadism
(n = 1), and osteoporosis (n = 1). Of 7 children with
growth velocity deceleration (3 boys, 4 girls), 4 were fo-
und to be GH-deficient. One child died prior to initiation
of biosynthetic human growth hormone therapy; the re-
maining 3 patients continue their GH substitution therapy.
Fifteen patients showed no endocrine disorders (Fig. 2).
As presented in Table 1, hypogonadotropic hypo-
gonadism was the first complication observed after
completion of the treatment (in the first 3 months post-
therapy). Growth velocity deceleration was noted be-
tween 4 and 24 months following the treatment. Prima-
ry hypothyroidism was diagnosed between 7 and
36 months. None of the patients was diagnosed with
secondary hypothyroidism. Osteoporosis was noted in
1 child with GH deficiency as late as almost 24 months
after medulloblastoma treatment (Table 1).
Figure 1. Endocrine disorders in children after medulloblastoma
treatment
Figure 2. Number of children with particular endocrine disor-
ders
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Discussion
The recently observed improvement in therapeu-
tic outcome in CSN malignancies has resulted in the
increasing survival of patients and has revealed the
issue of late endocrine complications. Such sequelae
may affect the secretion of one or more hormones and
occur at various time intervals following completion
of the treatment. Prior to the therapy, none of the pa-
tients from the investigated group demonstrated any
endocrine abnormalities. However, after the treatment
endocrine disorders were observed in 8 of the 23 chil-
dren (34%). These disorders included growth deficien-
cy, primary hypothyroidism, hypogonadotropic hypo-
gonadism, and osteoporosis. Three patients develo-
ped more than one endocrinopathy. The prevalence
of complications and their onset following completion
of therapy were not dependent on age or sex of the
patients.
The most common finding was growth velocity de-
celeration, which was seen within the 2 years after tre-
atment in 7 of the 23 patients; this observation is in
accordance with data reported by other authors [1, 2].
In the present material, in 50% of the cases the cause
of this disorder was growth hormone deficiency, pro-
bably resulting from the total irradiation dose, i.e. 35Gy,
with an increased dose of 54Gy applied to the site of
the removed tumour. As it follows from reports of nu-
merous authors, GH deficiency usually occurs when
the total dose exceeds 30Gy [1], while a dose of
18–30Gy may result in GH deficiency in approximately
1/3 of patients. A dose below 18Gy [7] is believed to be
safe, although a few authors suggest that GH deficien-
cy may develop even at lower irradiation doses, well
below 18Gy. In the present material, in 3 of 7 patients
with growth velocity deceleration, in whom no GH defi-
ciency was detected, growth delay might have resul-
ted from damage to the spinal growth cartilages du-
ring spinal cord irradiation [1] and/or additional injury
in the course of chemotherapy [9] Yet, in these patients,
GH deficiency developing later in life cannot be ruled
out as the cause of growth deficiency; similarly, these
2 disorders (GH deficiency and damage to the growth car-
tilages) cannot be excluded in patients without growth
abnormalities detected within 3 years following medul-
loblastoma treatment completion. Such a conclusion fol-
lows from the GH deficiency observed by other authors
developing as late as 25 years after treatment comple-
tion [12], and the increasing incidence of growth defi-
ciency, which is observed in as many as 70–80% with
increasing time after medulloblastoma treatment [1,2].
The second most common endocrinopathy enco-
untered in the investigated group was primary hypo-
thyroidism, observed in 3 of 23 patients (13%). No se-
condary hypothyroidism was noted, however, which
may be explained by a higher sensitivity to irradiation
exhibited by thyreocytes as compared to hypophyseal
thyreotropes. This is confirmed by the ten times higher
prevalence of primary, as compared to secondary,
hypothyroidism (30–50% vs. 3–6%) observed in ano-
ther group of patients following spinal cord irradiation
with a dose exceeding 10Gy [17]. The onset of hypo-
thyroidism was noted in the present group 7 months
after completion of therapy at the earliest, while 2 pa-
tients demonstrated hypothyroidism within 24 months
post-therapy, i.e. somewhat earlier than data reported
by other authors (the earliest reported occurrence was
10 months after therapy, with the mean time of 41 mon-
ths)[1]. It should be stressed that in investigations car-
ried out by other authors, the majority of hypothyro-
idism cases manifested later than 3 years after therapy
completion, even as late as 18 years [1]. The data indi-
cate the necessity of monitoring thyroid function for at
least 20 years after medulloblastoma treatment, sta-
ring in the first 6 months post-therapeutically.
Precocious puberty, delayed puberty, and no pro-
gress in puberty resulting from hypothalamic or gona-
dal damage (hypogonadism) are well documented
complications of radio and chemotherapy in children
[1, 2]. The degree of gonadal damage depends on the
age at therapy initiation and the cytotoxicity of the em-
ployed chemotherapy. The testes are more sensitive
Table 1. Time of the onset of particular symptoms after completion of therapy
Time of symptom onset after completion
of therapy (in months) 0–3 4–6 7–12 13–18 19–24 25–36
Growth velocity deceleration — GH deficiency   n = 1 n = 1   n = 2  
Other causes of growth velocity deceleration   n = 2 n = 1      
Primary hypothyroidism     n = 1   n = 1 n = 1
Osteoporosis         n = 1  
Hypogonadotropic hypogonadism n = 1          
n — number of patients manifesting a given disorder
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to the toxic effects of chemo and radiotherapy than are
the ovaries [1]. With the chemotherapy and radiothe-
rapy protocol employed in the investigated group, hy-
pogonadism resulting from damage to the hypotha-
lamus (hypogonadotropic hypogonadism) was dia-
gnosed in one girl (4.3%) 3 months after therapy com-
pletion. Within the three-month follow-up, no gona-
dal damage was observed. The available literature
reports the incidence of this complication in medul-
loblastoma patients below 15%, but it is the most fre-
quently diagnosed complication within 3 years of the
therapy[17,18]. A similar incidence rate is also re-
ported in the case of secondary dysfunction of the
hypothalamo-hypophyseal-adrenal axis [17, 24, 25].
In the presented material, not a single case of adre-
nal insufficiency was noted. The assessment was, ho-
wever, based on baseline cortisol and ACTH values
rather than post-ACTH and insulin-mediated hypo-
glycaemia stimulation levels, as has been suggested
by some authors.
A single case of osteoporosis was observed in the
presented group; the disorder developed 2 years after
the completion of therapy. The complication seemed
to be secondary to the GH deficiency detected in this
patient. Osteoporosis may be also expected in patients
with hypogonadism, especially when sex hormone
substitution is delayed.
According to data from the present investigation and
reports available in the literature, post-medulloblasto-
ma treatment endocrinopathies may develop starting
in the initial months after treatment and up to as late as
25 years post therapy. In view of the risk of relapse and
development of complications other than those of en-
docrine character, there is a need for close collabora-
tion between oncologists, neurosurgeons, and endo-
crinologists in monitoring potential disorders. The pre-
sent authors suggest the following protocol for diagno-
sing and monitoring endocrine disorders:
I. Prior to the initiation of treatment (chemotherapy
and radiotherapy) — auxological examinations: height,
weight, evaluation of growth velocity using growth
charts appropriate for a given population, assessment
of puberty according to Tanner’s scale, as well as hor-
monal determinations: LH, FSH, ACTH, cortisol, TSH,
fT4, fT3, PRL, and IGF-1.
II. After completion of treatment: auxological and
hormonal assessment as before therapy, to be repe-
ated every 6 months up to 4 years after completion of
treatment. Subsequently, every year: auxological as-
sessment until the patient completes the process of
growing and sexual maturation, and hormonal deter-
minations throughout his/her entire life.
III. Prior to treatment and every year afterwards,
imaging studies should be performed including
bone age (left wrist and hand X-ray — to be repe-
ated until the completion of growth), thyroid ultra-
sound, ultrasound of the minor pelvis in girls, and
densitometry in patients with GH or sex hormone
deficiency.
The protocol of examinations should focus on clini-
cal symptoms of endocrine disorders:
*determinations of gonadotropins levels and ultra-
sound of the minor pelvis are pointless before puberty;
in post-pubertal patients, these examinations should
be performed in case the patient presents with clinical
pubertal disturbances,
**estimation of IGF-1 is indicated in patients with
decelerated growth velocity as detected by auxology.
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